memantine has been researched along with Depression, Involutional in 27 studies
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
Excerpt | Relevance | Reference |
---|---|---|
"Drugs that target glutamate neuronal transmission, such as memantine, offer a novel approach to the treatment of late-life depression, which is frequently comorbid with cognitive impairment." | 9.41 | Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression. ( Grzenda, A; Laird, KT; Lavretsky, H; Siddarth, P; Yeargin, J, 2021) |
"We review the possible causes of catatonia and pharmacologic treatments for the condition and highlight the possible benefits of N-methylD-aspartic acid receptor antagonists such as memantine in the treatment of catatonia." | 6.47 | Memantine and catatonia: a case report and literature review. ( Catalano, G; Catalano, MC; Kahn, D; Obregon, DF; Velasco, RM; Wuerz, TP, 2011) |
"Drugs that target glutamate neuronal transmission, such as memantine, offer a novel approach to the treatment of late-life depression, which is frequently comorbid with cognitive impairment." | 5.41 | Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression. ( Grzenda, A; Laird, KT; Lavretsky, H; Siddarth, P; Yeargin, J, 2021) |
"Adult outpatients with major depressive disorder and partial response or nonresponse to their current antidepressant (as indicated by a 17-item Hamilton Depression Rating Scale score of ≥ 16 at baseline) were randomized (from July 2006-December 2011) to add memantine (flexible dose 5-20 mg/d, with all memantine group participants reaching the dose of 20 mg/d) (n = 15) or placebo (n = 16) to their existing treatment for 8 weeks." | 5.17 | Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. ( Deligiannidis, KM; Landolin, CS; Patel, JK; Rothschild, AJ; Smith, EG; Ulbricht, CM, 2013) |
"As a non-competitive N-methyl-d-aspartate receptor antagonist, memantine has been used to treat major mental disorders including schizophrenia, bipolar disorder, and major depressive disorder (MDD)." | 5.01 | Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials. ( Cai, DB; He, SH; Ng, CH; Ning, YP; Peng, XJ; Ungvari, GS; Xiang, YT; Yang, XH; Zhang, QE; Zheng, W; Zhou, YL; Zhu, XM, 2019) |
"We conducted a systematic review and meta-analysis on whether memantine was beneficial for the treatment of depressive symptoms in major depressive disorder (MDD) and bipolar disorder (BD)." | 4.95 | A Meta-Analysis of Memantine for Depression. ( Iwata, N; Kishi, T; Matsunaga, S, 2017) |
" No withdrawal was observed due to the drugs' adverse effects." | 2.94 | Comparison of the efficacy and safety of melatonin and memantine in the alleviation of cognitive impairments induced by electroconvulsive therapy: A randomized clinical trial. ( Abbasinazari, M; Badri, T; Ghassab-Sahebkar, A; Keshvari, N; Qobadighadikolaei, R; Sarraf, N, 2020) |
"Forty patients diagnosed with a major depressive disorder for which ECT was indicated as a treatment for their current episode were randomly allocated to either the memantine (5mg/day) group or the placebo group." | 2.80 | Memantine in the prevention or alleviation of electroconvulsive therapy induces cognitive disorders: A placebo controlled trial. ( Abbasinazari, M; Adib-Eshgh, L; Beyraghi, N; Dabir, S; Jafari, R; Rostami, A, 2015) |
"Memantine was at least as effective with regard to drinking as escitalopram." | 2.73 | Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication. ( Alho, H; Lahti, J; Lönnqvist, J; Muhonen, LH; Sinclair, D, 2008) |
"Memantine is an uncompetitive NMDA receptor antagonist, approved for treatment of Alzheimer's disease (AD) that in contrast to other NMDA receptor antagonists at therapeutic doses does not induce highly undesirable side effects." | 2.58 | The role of memantine in the treatment of major depressive disorder: Clinical efficacy and mechanisms of action. ( Amidfar, M; Kim, YK; Quevedo, J; Réus, GZ, 2018) |
"We review the possible causes of catatonia and pharmacologic treatments for the condition and highlight the possible benefits of N-methylD-aspartic acid receptor antagonists such as memantine in the treatment of catatonia." | 2.47 | Memantine and catatonia: a case report and literature review. ( Catalano, G; Catalano, MC; Kahn, D; Obregon, DF; Velasco, RM; Wuerz, TP, 2011) |
"Major depressive disorder is a common, recurrent illness." | 1.62 | Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior. ( Chen, BK; Denny, CA; Hunsberger, HC; Luna, VM; Mastrodonato, A; McGowan, JC; Rubinstenn, G; Shannon, ME; Stackmann, M, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 10 (37.04) | 29.6817 |
2010's | 11 (40.74) | 24.3611 |
2020's | 6 (22.22) | 2.80 |
Authors | Studies |
---|---|
Fava, M | 1 |
Stahl, SM | 1 |
De Martin, S | 1 |
Mattarei, A | 1 |
Bettini, E | 1 |
Comai, S | 1 |
Alimonti, A | 1 |
Bifari, F | 1 |
Pani, L | 1 |
Folli, F | 1 |
Guidetti, C | 1 |
Furlan, A | 1 |
Sgrignani, J | 1 |
Locatelli, P | 1 |
Cavalli, A | 1 |
O'Gorman, C | 1 |
Traversa, S | 1 |
Inturrisi, CE | 1 |
Pappagallo, M | 1 |
Manfredi, PL | 1 |
Schneider, LS | 1 |
Lavretsky, H | 2 |
Laird, KT | 2 |
Krause-Sorio, B | 1 |
Heimberg, BF | 1 |
Yeargin, J | 2 |
Grzenda, A | 2 |
Wu, P | 1 |
Thana-Udom, K | 1 |
Ercoli, LM | 1 |
Siddarth, P | 2 |
Sarraf, N | 1 |
Badri, T | 1 |
Keshvari, N | 1 |
Ghassab-Sahebkar, A | 1 |
Qobadighadikolaei, R | 1 |
Abbasinazari, M | 2 |
Chen, BK | 1 |
Luna, VM | 1 |
Shannon, ME | 1 |
Hunsberger, HC | 1 |
Mastrodonato, A | 1 |
Stackmann, M | 1 |
McGowan, JC | 1 |
Rubinstenn, G | 1 |
Denny, CA | 1 |
Amidfar, M | 1 |
Réus, GZ | 1 |
Quevedo, J | 1 |
Kim, YK | 1 |
Zheng, W | 1 |
Zhu, XM | 1 |
Zhang, QE | 1 |
Cai, DB | 1 |
Yang, XH | 1 |
Zhou, YL | 1 |
Ungvari, GS | 1 |
Ng, CH | 1 |
He, SH | 1 |
Peng, XJ | 1 |
Ning, YP | 1 |
Xiang, YT | 1 |
Smith, EG | 1 |
Deligiannidis, KM | 1 |
Ulbricht, CM | 1 |
Landolin, CS | 1 |
Patel, JK | 1 |
Rothschild, AJ | 1 |
Dutta, A | 1 |
McKie, S | 1 |
Deakin, JFW | 1 |
Adib-Eshgh, L | 1 |
Rostami, A | 1 |
Beyraghi, N | 1 |
Dabir, S | 1 |
Jafari, R | 1 |
Ford, AH | 1 |
Almeida, OP | 1 |
Kishi, T | 1 |
Matsunaga, S | 1 |
Iwata, N | 1 |
Muhonen, LH | 4 |
Lahti, J | 3 |
Sinclair, D | 1 |
Lönnqvist, J | 4 |
Alho, H | 4 |
Kyomen, HH | 1 |
Whitfield, TH | 1 |
Hashimoto, K | 1 |
Haukka, J | 1 |
Saarikoski, ST | 1 |
Obregon, DF | 1 |
Velasco, RM | 1 |
Wuerz, TP | 1 |
Catalano, MC | 1 |
Catalano, G | 1 |
Kahn, D | 1 |
Szakacs, R | 1 |
Janka, Z | 1 |
Kalman, J | 1 |
Owen, RT | 1 |
Zarate, CA | 2 |
Singh, JB | 1 |
Quiroz, JA | 1 |
De Jesus, G | 1 |
Denicoff, KK | 1 |
Luckenbaugh, DA | 1 |
Manji, HK | 1 |
Charney, DS | 1 |
Pittenger, C | 1 |
Naungayan, C | 1 |
Kendell, SF | 1 |
Coric, V | 1 |
Malison, R | 1 |
Krystal, JH | 1 |
Sanacora, GS | 1 |
Kollmar, R | 1 |
Markovic, K | 1 |
Thürauf, N | 1 |
Schmitt, H | 1 |
Kornhuber, J | 1 |
Maeng, S | 1 |
Munoz, C | 1 |
Yulan, N | 1 |
Achaval, V | 1 |
Appiani, F | 1 |
Carroll, BT | 1 |
Juva, K | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Treatment of Geriatric Depression With Mild Cognitive Impairment: A Double-blind Placebo-Controlled Trial of Namenda (Memantine) Augmentation of Lexapro (Escitalopram) in Depressed Patients at Least 60 Years of Age[NCT01902004] | Phase 4 | 115 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders[NCT00344682] | Phase 4 | 31 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
Phase Four Double-Blind Randomized Comparative Study on Thestudy on the Efficacy of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism[NCT00368862] | Phase 4 | 80 participants | Interventional | 2005-12-31 | Completed | ||
Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment[NCT01876823] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Neuropsychological battery of tests which included the following domains: learning, delayed recall, and executive functioning. Raw scores were transformed to z-scores for each test score of interest for each participant, and then averaged. These z-scores were averaged within each neuropsychological domain to produce composite scores and then averaged over all tests to calculate a global performance score. Higher scores are indicative of better performance. (NCT01902004)
Timeframe: Measured at 6 months and 12 months
Intervention | z score (Mean) | ||
---|---|---|---|
Baseline | 6 Months | 12 Months | |
Escitalopram and Memantine | .02 | 0.03 | .15 |
Escitalopram and Placebo | -.04 | -.1 | -.26 |
Clinician administered scale measures severity of depressive symptoms. This measure includes 24 items. Response options vary item to item and include the following ranges: [0-2], [0-3], and [0-4]. A score of 0 suggests absence of symptoms and/or difficulties and higher scores represent more severe difficulties. Possible overall score range [0-74], higher scores representing more severe difficulties. (NCT01902004)
Timeframe: Measured at 3 months; 6 months and 12 months
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Baseline | 3 Months | 6 Months | 12 Months | |
Escitalopram and Memantine | 17.8 | 6.0 | 5.9 | 7.2 |
Escitalopram and Placebo | 17.7 | 6.7 | 6.9 | 5.4 |
Clinician administered item scale measures severity of depressive symptoms. The 10 items are measured on a 7-point scale ranging from 0 to 6; creating a total range of 0-60. A score of 0 suggests absence of symptoms and higher scores represent greater severity of depression.Severity gradations for the MADRS have been proposed (9-17 = mild, 18-34 = moderate, and ≥ 35 = severe). Treatment remission is defined as an endpoint total score ≤ 10. (NCT01902004)
Timeframe: Measured at 3 months; 6 months and 12 months
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Baseline | 3 Months | 6 Months | 12 Months | |
Escitalopram and Memantine | 16.7 | 7.1 | 6.0 | 8.8 |
Escitalopram and Placebo | 14.8 | 8.7 | 8.6 | 8.0 |
The UKU (Udvalg for Kliniske Undersogelser) Side Effect Rating Scale organizes symptoms into 4 categories (i.e., Psychic, Neurologic, Autonomic, Other) containing 8-19 symptoms each. Each symptom receives a score for degree and causal relationship. Degree is scored between 0-3 with higher scores being more severe. Causal relationship is scored as improbable, possible, or probable. (NCT01902004)
Timeframe: Measured at 3, 6 months and 12 months
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
3 Months | 6 Months | 12 Months | |
Escitalopram and Memantine | 3 | 3 | 1 |
Escitalopram and Placebo | 2 | 5 | 0 |
Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Scores > 30 indicate severe anxiety. (NCT00344682)
Timeframe: baseline & week 8
Intervention | units on a scale (Mean) |
---|---|
Placebo | -4.13 |
Memantine | -5.53 |
The 16 item Quick Inventory of Depressive Symptomatology (QIDS-SR16) (Rush et al. 2003) is designed to assess the severity of depressive symptoms, with higher scores representing more severe forms of depression. When complete, the QIDS are scored by summing responses to obtain a total score ranging from 0 to 27. Either appetite increase or decrease, but not both, are used to calculate the total score. Weight increase or decrease, but not both, are used to calculate the total score. Scores 0-5 indicate no severity of depression; 6-10 is mild; 11-15 is moderate; 16-20 is severe; 21-27 is very severe levels of depression. Participants were evaluated at baseline and at weeks 1, 2, 3, 4, 6 & 8. (NCT00344682)
Timeframe: baseline & week 8
Intervention | units on a scale (Mean) |
---|---|
Placebo | -3.69 |
Memantine | -6.47 |
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6 on 10 items. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in response rate and remission rate were assessed for secondary measures. (NCT00344682)
Timeframe: baseline and week 8
Intervention | units on a scale (Mean) |
---|---|
Placebo | -10.75 |
Memantine | -7.13 |
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in MADRS score was a primary measure. (NCT00344682)
Timeframe: Baseline & week 8
Intervention | units on a scale (Mean) |
---|---|
Placebo | -7.25 |
Memantine | -7.13 |
Change in 24-item Hamilton Rating Scale for Depression (HAMD) scores from baseline to Week 48: HAMD measures depression severity based on a series of 24 items items. The range of HAMD total score is 0-74; 0 indicates no depressive symptoms and a maximum HAMD score is a 74, where the greater the score indicates more significant psychopathology. In this study, moderate to severe depression is considered a HAMD-24 greater than 14. (NCT01876823)
Timeframe: Baseline, Week 48
Intervention | scores on a scale (Mean) |
---|---|
Es-citalopram and Memantine Treatment | -15.2 |
Change in Selective Reminding Test-Delayed Recall scores from baseline to Week 48: SRT Delay is administered 15 minutes after the immediate recall portion. Patients are asked to remember as many of the words as they can from the 6 trials. Maximum raw score is a 12 for free recall. If a patient is unable to recall a word, they are given a chance to recognize it among three incorrect word choices. Maximum raw score for recognition is 12. The greater the score on the delayed recall portion, the better the patient does on the assessment. (NCT01876823)
Timeframe: Baseline, Week 48
Intervention | units on a scale (Mean) |
---|---|
Es-citalopram and Memantine Treatment | 1.2 |
Change in Selective Reminding Test-Total Immediate Recall (SRT-IR) scores from baseline to Week 48: Measures word recall (maximum 12 words per trial, across 6 trials). Maximum total recall score across 6 trials is 72; minimum recall is 0 across 6 trials. The higher the raw score, the better the patient did at recalling the target words. The unit of measure is the raw score, or the sum of the number of words recalled across all 6 trials. (NCT01876823)
Timeframe: baseline, 48 weeks
Intervention | units on a scale (Mean) |
---|---|
Es-citalopram and Memantine Treatment | 7.5 |
Change in Trails A scores from baseline to Week 48: Measures attention and executive function. It asks patients to connect numbers from 1-25 in numerical order as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
Intervention | seconds (Mean) |
---|---|
Es-citalopram and Memantine Treatment | 1.9 |
Change from baseline to Week 48 on Trails B: Measures attention and executive function. It asks patients to connect numbers and letters in numerical to alphabetical order from (1-13 and A-L) as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers and letters, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
Intervention | seconds (Mean) |
---|---|
Es-citalopram and Memantine Treatment | -36.3 |
Change in Wechsler Memory Scale-III scores from baseline to Week 48: The WMS-III Visual Reproduction sub-test was used to measure visual working memory and delayed memory. Patients were shown pictures of four drawings and were asked to reproduce them from memory immediately after seeing them, and 25 minutes after seeing them. The four scores are summed and the greater the total raw score, the better the patient did on the assessment. The maximum raw score for this test is a 41 on both the immediate and delayed portions (the overall range is 0-82 points). The change score is calculated using the total scores of both the immediate and delayed portions. (NCT01876823)
Timeframe: Baseline, Week 48
Intervention | units on a scale (Mean) |
---|---|
Es-citalopram and Memantine Treatment | 9.9 |
The CDR is a numeric rating scale that is used to quantify the severity of one's cognitive function. The scale goes from 0=normal; 0.5=mild cognitive impairment; 1 to 3=mild to moderate/severe dementia. CDR was used a dichotomous outcome measure (no=0; yes=1). (NCT01876823)
Timeframe: Baseline, Week 48
Intervention | participants (Number) |
---|---|
Es-citalopram and Memantine Treatment | 1 |
The CGI Cognitive Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses from the entire group were calculated. Mean at final visit and baseline is reported below. (NCT01876823)
Timeframe: Baseline, Week 48
Intervention | units on a scale (Mean) | |
---|---|---|
CGI-Cognitive Change (Baseline) | Clinical Global Impression-Cogntive Change (WK 48) | |
Es-citalopram and Memantine Treatment | 3.6 | 2.7 |
The CGI Depression Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses were calculated for the entire group. Mean at final visit has been reported below. Higher mean at baseline indicates a decrease in depression scores. (NCT01876823)
Timeframe: Baseline, Week 48
Intervention | units on a scale (Mean) | |
---|---|---|
Cognitive Global Impression at Baseline | Cognitive Global Impression at Final Visit (WK 48) | |
Es-citalopram and Memantine Treatment | 4.1 | 2.1 |
"Somatic side effect rating scale which includes 26 common somatic side effects associated with previous medication clinical trials; rated by the study physician. Factors were dichotomized to yes or no responses on this scale, which equated to the symptom being either present or not present. Yes and no responses were given a value of 0 (no) or 1 (yes). Responses from the entire group were calculated and the mean at baseline and the last visit is reported below." (NCT01876823)
Timeframe: Baseline, Week 48
Intervention | units on a scale (Mean) | |
---|---|---|
Treatment Emergent Side Effects (Baseline) | Treatment Emergent Side Effects (WK 48) | |
Es-citalopram and Memantine Treatment | 6.6 | 3.2 |
11 reviews available for memantine and Depression, Involutional
Article | Year |
---|---|
Esmethadone-HCl (REL-1017): a promising rapid antidepressant.
Topics: Alzheimer Disease; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagoni | 2023 |
The role of memantine in the treatment of major depressive disorder: Clinical efficacy and mechanisms of action.
Topics: Animals; Behavior, Animal; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Memantine | 2018 |
Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials.
Topics: Bipolar Disorder; Cognition; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combinat | 2019 |
Ketamine and other potential glutamate antidepressants.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Glutamic Acid; Humans; Ketamine; Memanti | 2015 |
Management of Depression in Patients with Dementia: Is Pharmacological Treatment Justified?
Topics: Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; | 2017 |
A Meta-Analysis of Memantine for Depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Memantine | 2017 |
Emerging role of glutamate in the pathophysiology of major depressive disorder.
Topics: Brain; Depressive Disorder, Major; Glutamic Acid; Humans; Ketamine; Memantine; Receptors, AMPA; Rece | 2009 |
Memantine and catatonia: a case report and literature review.
Topics: Aged, 80 and over; Catatonia; Depressive Disorder, Major; Dopamine Agents; Female; Humans; Memantine | 2011 |
The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression.
Topics: Amantadine; Antidepressive Agents; Depressive Disorder, Major; Glutamates; Hippocampus; Humans; Mema | 2012 |
Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Excitatory Amino Acid Antagonists | 2012 |
The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects.
Topics: Amantadine; Depressive Disorder, Major; Dopamine Agents; Excitatory Amino Acid Antagonists; Humans; | 2007 |
8 trials available for memantine and Depression, Involutional
Article | Year |
---|---|
A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints.
Topics: Aged; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female | 2020 |
Comparison of the efficacy and safety of melatonin and memantine in the alleviation of cognitive impairments induced by electroconvulsive therapy: A randomized clinical trial.
Topics: Adult; Aged; Cognition; Cognitive Dysfunction; Depressive Disorder, Major; Electroconvulsive Therapy | 2020 |
Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression.
Topics: Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Meman | 2021 |
Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Man | 2013 |
Memantine in the prevention or alleviation of electroconvulsive therapy induces cognitive disorders: A placebo controlled trial.
Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Electroconvulsive Thera | 2015 |
Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication.
Topics: Adult; Aged; Alcoholism; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, | 2008 |
A double-blind, placebo-controlled study of memantine in the treatment of major depression.
Topics: Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Excitatory Amino Acid | 2006 |
Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence.
Topics: Adult; Aged; Alcoholism; Ambulatory Care Facilities; Citalopram; Comorbidity; Depressive Disorder, M | 2008 |
8 other studies available for memantine and Depression, Involutional
Article | Year |
---|---|
Alzheimer's and Dementia Guidelines and Tables.
Topics: Alzheimer Disease; Antipsychotic Agents; Depressive Disorder, Major; Hallucinations; Humans; Memanti | 2023 |
Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior.
Topics: Animals; Depressive Disorder, Major; Female; Ketamine; Male; Memantine; Mice; Receptors, N-Methyl-D- | 2021 |
Psychosis in the elderly.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents | 2009 |
Age at onset of first depressive episode as a predictor for escitalopram treatment of major depression comorbid with alcohol dependence.
Topics: Adult; Age of Onset; Aged; Alcoholism; Antidepressive Agents; Citalopram; Comorbidity; Depressive Di | 2009 |
Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence.
Topics: Adult; Alcoholism; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; | 2011 |
Visual hallucinations from the addition of riluzole to memantine and bupropion.
Topics: Adult; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Drug Interactions; Drug Th | 2006 |
Ketamine followed by memantine for the treatment of major depression.
Topics: Administration, Oral; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combin | 2008 |
Memantine in major depression with catatonic features.
Topics: Aged, 80 and over; Antiparkinson Agents; Catatonia; Depressive Disorder, Major; Female; Humans; Mema | 2008 |